Uterine Serous Carcinoma Responds to the WEE1 Inhibitor Adavosertib.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-043
Abstract: The overall response rate to adavosertib was 29.4%; no biomarkers predicting response were found. read more here.
Keywords: serous carcinoma; carcinoma responds; uterine serous; wee1 inhibitor ... See more keywords